Observed performance metrics in laboratory models
Observed performance metrics in laboratory models
Free shipping worldwide on all orders. This includes delivery to APO, DPO & FPO addresses.
Domestic: 5-7 business days.
International: 10-14 business days.
No express shipping due to timing inconsistencies from couriers.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
Unordered list
Bold text
Emphasis
Superscript
Subscript
Research summary on Testolone (also known as RAD-140).
Ostarine, also known as Enobosarm or MK-2866, is a non-steroidal selective androgen receptor modulator.
RAD-140 (Testolone) is a Selective Androgen Receptor Modulator (SARM) — studied for its high anabolic-to-androgenic ratio and potential neuroprotective benefits.
In research settings, it has been shown to:
✔ Stimulate significant muscle growth.
✔ Enhance strength and power output.
✔Exhibit neuroprotective effects in research models.
📏 LEAN MUSCLE RETENTION:
RAD-140 has been observed to induce robust gains in lean muscle mass, even at low research dosages.
⚡ PERFORMANCE ENHANCEMENT:
Its anabolic effects contribute to improvements in maximal strength and explosive power.
🧩 BRAIN HEALTH:
Animal studies suggest RAD-140 may offer neuroprotective benefits by reducing cell death in neurons.
Design, Synthesis, and Preclinical Characterization of RAD140 — ACS Medicinal Chemistry Letters (2011).
https://exaly.com/paper-pdf/51248120/citation-report.pdf
Selective Androgen Receptor Modulator RAD140 Is Neuroprotective in Cultured Neurons and Kainate-Lesioned Male Rats — Endocrinology (2014).
https://healthedacademy.com/rad-140-vs-rad-150/
Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models — Clinical Cancer Research (2017).
Phase I Dose-Escalation Study of the Selective AR Modulator RAD140 in Metastatic Breast Cancer — Annals of Oncology (2019 abstract; full paper later in Clinical Breast Cancer, 2022).
https://www.annalsofoncology.org/article/S0923-7534%2819%2958565-9/fulltext
Explore the best stack options.